Hepatocellular carcinoma (HCC) is an aggressive tumor and the third leading cause of cancer-related death worldwide. Ovarian carcinoma immunoreactive antigen-like protein 2 (OCIAD2) has been found frequently methylated in various cancers, including HCC. The aim of the present study was to investigate the role of OCIAD2 in HCC progression. We analyzed liver hepatocellular carcinoma patients' data from the Cancer Genome Atlas (TCGA), including data extracted from 371 HCC tissues and 50 adjacent normal liver tissues. The RNA sequencing and DNA methylation data revealed that OCIAD2 were significantly hypermethylated and its expression level in the tumor tissues was much lower than that in the corresponding adjacent normal tissues. The methylation level in the promoter was negatively correlated with the expression level of OCAID2. Treatment of HCC cell lines with the DNA methylation inhibitor 5-aza-2′-deoxycitydine (5-Aza) induced a significant increase in the OCIAD2 mRNA and protein. Knocking-down OCIAD2 led to an increased colony formation, migration and invasion dramatically, accompanying with an enhanced expression of MMP9 and activation of AKT and FAK. Inhibition of AKT signaling restored OCIAD2-mediated changes in HCC cell clonogenic growth, migration and invasion. Survival analysis of HCC patient's data indicated patients with a higher expression ratio of OCIAD2/MMP9 had a shorter overall survival than those with a lower expression ratio of OCIAD2/MMP9. Overall, our data indicate that reduced expression of OCIAD2 by DNA hypermethylation plays an important role in HCC tumor growth and invasion. Hypermethylation of OCIAD2 may contribute to HCC treatment development.
Introduction
Hepatocelluar carcinoma (HCC) is a primary malignancy of the liver and the third leading cause of cancer deaths worldwide. More than 500 000 new cases occur annually worldwide (1, 2) . Despite advances in many aspects of HCC treatment, surgical resection and liver transplantation are considered as the only potentially curative treatments for the early diagnosed HCC patients. The 5-year survival rate of HCC patients after curative resection remains 30-70% (3) (4) (5) (6) . However, the median survival for most HCC patients with the advanced HCC is approximately 6-20 months after diagnosis (1, 5, 7) . The high mortality rate of HCC is mainly due to a late diagnosis. So far, only one chemotherapeutic agent, sorafenib, has been approved for the treatment of patients with advanced HCC and its effect on the patient survival is modest (8) (9) (10) (11) . Therefore, there is an urgent need in discovering effective biomarkers for early diagnosis and development of new treatment strategies for HCC.
The development of HCC is a process with a gradual accumulation of genetic and epigenetic alterations, leading to the activation of oncogenes and suppression of tumor suppressor genes. Epigenetics is defined as heritable changes in gene activity and expression that occur without alteration in DNA sequence. DNA methylation, histone modification and non-coding RNA (ncRNA)-associated gene silencing are currently considered to initiate and sustain epigenetic changes. Dysregulation of DNA methylation such as global hypomethylation and site-specific hypermethylation, leads to aberrant expression profiles of genes necessary for cancer progression, which have been observed in various human cancers, including HCC (5, 12, 13) . Global DNA hypomethylation is often seen concomitantly with hypermethylation of CpG islands (14) . Promoter CpG island hypermethylation is associated with silencing of various genes involved in tumor suppression, cell cycle regulation, DNA repair, apoptosis regulation, etc. Accumulating data provides evidence that epigenetic defects in cancer may be potentially useful in cancer diagnosis and treatment (13) (14) (15) (16) (17) (18) (19) . Abnormal promoter methylation are associated with early pre-neoplastic alteration and can be detected in the normal epithelium of some patients, such as p16INK4A in breast cancer (15) and p15INK4B in leukemia (16) . Higher degrees of methylation are thought to associate with an increased risk for neoplastic transformation (13, (17) (18) (19) . DNA methylation status can also be used as prognostic indicators. Cheng et al. showed that the high CpG island methylated phenotype correlated with worse prognosis of HCC and could serve as a molecular marker for late stage and poor prognostic HCC (20) . Abnormal DNA methylation of several tumor suppressor genes have been associated with the development of HCC, such as RASSF1A, CDKN2A, CRABP1, GSTP1, CHRNA3, DOK1, SFRP1, GAAD45a, CDKN2B, and MZB1 (21) (22) (23) . Therefore, identification of methylation targets may clarify the specific molecular events involved in HCC progression, enabling improving the current strategies in the prevention, diagnosis, and treatment of HCC.
Ovarian carcinoma immunoreactive antigen-like protein 2 (OCIAD2), is an immunoreactive protein with unknown function (24) . The expression of OCIAD2 was diverse in different cancers. In lung adenocarcinoma, OCIAD2 was highly expressed in the invasive adenocarcinoma than that in the in situ adenocarcinoma (25, 26) . Nagata et al. analyzed 117 ovarian mucinous tumors and found OCIAD2 was highly expressed in the borderline tumor and carcinoma (51/74 cases, 69%) than that in the adenoma (6/43 cases, 14%) (27) . In contrast, the expression level of OCIAD2 level was significantly reduced in liver cancer and gastric stroma carcinoma, when compared with that in the corresponding normal tissues (28) . Low expression level of OCIAD2 was frequently observed in chronic lymphocytic leukemia and malignant pleural mesothelioma (29, 30) . Gene expression profiling showed that the brain-metastasis from triple-negative breast cancer had significantly reduced level of OCIAD2 compared to the in situ cancers (31) . A lower expression level of OCIAD2 was detected in glioblastoma rather than in anaplastic astrocytomas (32) . Hypermethylation of OCIAD2 in glioblastoma was associated with a dramatically reduction in the expression level of OCIAD2 (33) . Hypermethylated OCIAD2 was also observed in metastasis-associated fibroblasts of ovarian cancer (34) and HCC cell lines (6 out of 17) (22) .
So far, the role of OCIAD2 in cancer progression is still controversial. We evaluated OCIAD2 expression and DNA methylation data of HCC from The Cancer Genome Atlas (TCGA), including 371 tumor samples and 50 adjacent non-tumor samples. The mean value of OCIAD2 expression in HCC tumor tissues was significantly lower than that in the adjacent non-tumor tissues. OCIAD2 was hypermethylated in HCC compared with the adjacent non-tumor tissues.
Treatment of HCC cell lines with the DNA methylation inhibitor 5-aza-2′-deoxycitydine (5-Aza) induced a significant increase in the OCIAD2 mRNA and protein. Infection of the HCC cells with lentivirus-mediated shRNA achieved ~80% suppression of OCIAD2. Knocking-down OCIAD2 led to an increased colony formation, migration and invasion dramatically, accompanying with an enhanced expression of MMP9 and activation of AKT and FAK. Survival analysis of HCC patient's data indicated patients with a higher expression ratio of OCIAD2/MMP9 had a shorter overall survival than those with a lower expression ratio of OCIAD2/MMP9. Overall, our data indicates that downregulation of OCIAD2 by hypermethylation plays an important role in HCC tumor growth and invasion.
Results

The expression of OCIAD2 in human HCC and normal liver tissues
We compared OCIAD2 expression level in 371 tumors and 50 non-tumor adjacent tissues, and paired 50 tumor tissues with their corresponding non-tumor adjacent tissues from the same individuals. Significantly reduced expression of OCIAD2 was observed in the HCC tissues (P < 0.05) as shown in the Figure 1A . We also compared the methylation level of OCAID2 in the HCC tumors and non-tumor adjacent tissues. The methylation data from TCGA was detected by Illumina's Infinium Human Methylation450 Beadchip. The genomic coordinates of CpG, exons and coding regions were obtained from the Illumina annotation files. In order to achieve a comprehensive assessment of the regional methylation, the probes were designed across multiple sub-regions of this gene. There are total 12 CpG sites with methylation values for OCIAD2, including promoter region TSS200 and TSS1500 (200 bp and 1500 bp blocks upstream of the transcription start site), 5′-untranslated region (5′-UTR), first exon, gene body, and 3′-UTR (Table 1) . High methylation levels of OCIAD2 in HCC were observed several regions, including 2 TSS200, TSS 1500, 5′-UTR, first exon and gene body (P < 0.05), when compared with the adjacent normal tissues. Low methylation sites included TSS 1500 and 3′-UTR (P < 0.05). No significant difference was found in other five methylation regions ( Figure 1B ).
To determine whether OCIAD2 methylation was correlated with its expression, we calculated the Pearson correlation coefficient for individual CpG sites as shown in the Figure 1B 
DNA methylation regulates OCIAD2 expression in the HCC cells
Based on the frequently reduced expression and hypermethylation of OCIAD2, we hypothesized that expression of OCIAD2 in HCC is regulated by epigenetic methylation. We analyzed the protein levels of OCIAD2 in three HCC cell lines using Western blot. The protein levels of OCIAD2 in Sk-Hep1 cells was much higher than the other five HCC cells (Figure 2A ). All these six HCC cell lines were treated with 5-Aza for 5 days and were harvested for protein and RNA analysis of OCIAD2. As shown in the Figure 2B&C , the RNA and protein levels of OCIAD2 were dramatically increased in all six HCC cells after 5-Aza treatment.
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Knockdown of the OCIAD2 expression in Sk-hep1 HCC cell line
In order to determine the potential role of OCIAD2, we perform RNA interference to knock down OCIAD2 in the Sk-hep1 cells. We used GFP conjugated shRNA lentivirus particle to verify the infection efficiency through a fluorescence microscope.
The infection efficiency in this cell line reached more than 80% as shown in the Figure 3A . Puromycin was added in the medium for selecting stably infected cells after 48 h of infection. The RNA and protein levels of OCIAD2 were significantly reduced in the cells infected with OCIAD2 shRNA, compared with the mockinfected cells ( Figure 3B and C). Two cell clones (C1 and C2) with stably transfected OCIAD2 shRNA were selected and used in the following experiments.
The role of OCIAD2 in colony formation, migration and invasion of HCC cells
To determine the effect of OCIAD2 on HCC cell growth, we compared the viability of the cells with/without stably infected shRNA. C1 and C2 cells with stably infected OCIAD2 shRNA had a higher colony formation capacity as compared to the cells infected with scrambled shRNA. The number of clones in C1 and C2 cells were 2.32 ± 0.04 times and 1.45 ± 0.03 times (P < 0.05; Figure 4A ) higher than that in the scramble cells, respectively. Our data indicated that OCIAD2 had a suppressive role in the clonogenic growth of HCC.
To assess the effect of OCIAD2 on HCC cell migration/invasion, we compared the migration and invasion capacity of the Sk-hep1 cells infected with either OCIAD2 shRNA or scrambled shRNA using wound healing and transwell assays. For the wound Corresponding CpG sites were noted in Table 1 healing assay, the confluence monolayer cells were wounded with perpendicular scratches using a sterile 200-μL pipette tip. As illustrated in Figure 4B , the percentage of open area in the parental Sk-hep1 cells infected with scrambled shRNA dropped to 94.7% and 53.3% at 6h and 24h after introduction of the perpendicular scratches, respectively. While the percentage of open area dropped to 83.2% and 20.5% (P < 0.01) in the C1 clone, and 89.6% and 24.0% (P < 0.01) in the C2 clone, respectively. Our data indicated that knocking-down OCIAD2 stimulated HCC cell migration. For the invasion assay, the transwells were precoated with 200 µL 0.15% matrigel. The cells infected with/without OCIAD2 shRNA in serum-free culture medium were seeded into the inserts and the cells traversed into the bottom of the filter counted. We compared the number of cells traversed through the matrigels. As shown in the Figure 4 , the number of C1 and C2 cells traversed through the matrigels was about 5.4 ± 0.8 and 3.5 ± 0.6 times higher (P < 0.01) than the cells infected with scrambled shRNA. Our data indicated that knocking-down OCIAD2 enhanced the invasive potential of HCC cells.
AKT was involved in the OCIAD2 mediated clonognenic survival and invasion of HCC cells
To further elucidate the mechanism underlying OCIAD2 induced clonogenic formation and invasion, we analyzed several important signal transduction pathways in OCIAD2 knocking down HCC cells. The protein levels of AKT, phospho-AKT, phospho-ERK 1/2, phospho-FAK were detected. As shown in the Figure 5 , knocking-down OCIAD2 in the Sk-hep1 cells resulted in a greater activation of AKT and FAK comparing to the control ( Figure 5A and B). No changes in phosphor-ERK 1/2 were observed (data did not show). Furthermore, the sk-hep1 cells with knocking down OCIAD2 were treated with AKT inhibitor LY294002 ( Figure 5C ). Inhibition of AKT restored the silence of OCIAD2-mediated changes in clonogenic formation and invasion, as shown in the Figure 5D and E. Our data indicate that AKT is a key mediator in OCIAD2-induced changes in HCC cells.
OCIAD2 mediated the expression of MMP9 in the HCC cells
MMP9 plays an important role in the migration and invasion of tumor cells. We measured the MMP-9 protein levels in the HCC cells infected with/without OCIAD2 shRNA. As shown in the Figure 6A , the expression of MMP9 was obviously elevated in the cells infected with OCIAD2 shRNA. The expression level of MMP9 was 4.3 ± 0.2 and 2.1 ± 0.1 folds higher in C1 and C2 clones, respectively, when compared with the cells infected with the scramble shRNA.
Correlation between the expression ratio of OCIAD2/ MMP9 and patients' survival
We compared MMP9 expression level in 371 tumors and 50 nontumor adjacent tissues, and paired 50 tumor tissues with their corresponding non-tumor adjacent tissues from the same individuals. Analysis of the RNA-seq data indicated that the expression level of MMP9 in the HCC tissues was significantly higher than that in the normal tissues in both unpaired and paired comparison ( Figure 6B ). We then did Kaplan-Meier analyses to determine the association between the relative expression of OCIAD2 & MMP9 and patients' overall survival. As shown in the Figure 6C , the ratio of OCIAD2/MMP9 was negatively associated with overall survival. The patients were stratified into two groups according to ratio of OCIAD2/MMP9. Regression analysis using Cox proportional hazards model showed that patients with a ratio of OCIAD2 to MMP9 expression higher than 1.3 had a longer survival than the patients with a lower ratio (P < 0.01, Hazard Ratio = 0.572).
Discussion
Methylation is the main epigenetic modification in humans and changes in methylation patterns play an important role in tumor progression. Indeed, tumor cells are characterized by a different methylation pattern from that of normal cells. Interestingly, both hypo-and hypermethylation events are observed in various cancers. Most of the CpG dinucleotides are methylated on cytosine residues. A global decrease in methylated CpG content in cancers is observed, which contributes to genomic instability and activation of soncogenes. CpG islands hypermethylation in promoters of specific genes has been shown as a critical hallmark in many cancer cells (35) . An increased number of tumor suppressor genes have been reported to be hypermethylation on the normally unmethylated CpG islands during tumorigenesis, which is correlated with loss of expression. So, it is necessary to test the methylation status of genes in various tumors in order to better understand their roles in carcinogenesis. Recently, abnormally methylation of OCIAD2 has been reported in many cancers and its role in tumor progression is unclear. Our study indicates for the first time that frequently epigenetic silenced OCIAD2 in HCC cancer tissues is associated with elevated HCC cell clonogenic survival and invasion capacity.
Methylation of CpG islands occurs genome-wede in regions related to protein coding genes (promoters, exons, untranslated regions, etc.) as well as in certain intergenic regions. Increased methylation in promoter is often negatively related with the gene expression level. 5′-UTR and 3′-UTR methylation levels might influence the elongation and termination of transcription. It has been reported that high density methylation of the 5′-UTR repressed gene expression (36) and hypermethylation of the 3′-UTR produced decreased gene expression, such as p 15INK4b gene in lymphomas and TrkB-T1 in astrocytes (37, 38) . CpG methylation in the first exon was tightly linked to transcriptional silencing (39) . On the other hand, CpG methylation in gene bodies showed a positive association with gene expression level (40) . According to the analysis results of OCIAD2 methylation, higher methylation was observed in promoter region loci TSS 1500, TSS200, 5′-UTR and first exon; and lower methylation levels in gene body and 3′-UTR sites in HCC tumors than that in the normal tissues. Analysis of the RNA sequencing data showed that OCIAD2 was highly expressed in HCC tumors than the adjacent normal tissue. The correlation of OCIAD2 expression and five significantly methylated CpG sites (promoter region and the first exon) was negatively associated, indicating that the hypermethylation of OCIAD2 played roles in regulating OCIAD2 expression. Additionally, our previous study revealed the expression of OCIAD2 was activated by TGF-β signal in HCC cells (28) . Up to 40% of HCC have increased TGF-β expression based on immunohistochemical analysis, and increased TGF-β levels in serum and urine are also observed in HCC patients (41, 42) . Accumulated studies indicate that TGF-β regulate DNA methylation in various cancers, such as prostate cancer, ovarian cancer and liver cancer (43) (44) (45) . Furthermore, the increase expression of OCIAD2 following the treatment with 5-Aza demonstrated that, at least partly, epigenetic silencing by hypermethylation of the OCIAD2 leads to a loss of OCIAD2 function, which may be an important factor in the HCC progression.
Although OCIAD2 expression has been reported dysregulated in various types of cancer, its regulatory roles in cancer progression is still unclear and appears to be tumor type-dependent. OCIAD2, which was observed expressed in most invasive lung adenocarcinomas, but nearly always negative in the normal lung tissues, could be a strong and specific biomarker for the diagnosis of lung adenocarcinoma (25, 46) . We analyzed lung cancer dataset GSE17710 found that higher expressed OCIAD2 was related with good prognosis of lung cancer patients, which was consistent with our results (Supplementary 1). However, Ishiyama et al. found that lung adenocarcinoma patients with OCIAD2 expression showed a better clinical outcome than those without OCIAD2 expression, and OCIAD2 expression showed an inverse correlation with lymphatic invasion, blood vessel invasion and lymph node metastasis (26) . In gliomas, OCIAD2 could discriminate patients who will experience short-term survival (≤ 1 year), as well as those with long-term survival (≥ 3 years) (47) . Microarray analysis showed that OCIAD2 might also play a role in malignant progression of astrocytomas (WHO grade III) to glioblastomas (WHO grade IV) by inhibition of tumorgenicity (32) . Besides cancer, OCIAD2 have also been studied in other diseases. Hypermethylated OCIAD2 was observed in HBV-associated hepatitis (48) . The expression level of OCIAD2 was significantly elevated in the brain of Alzheimer's disease patients and OCIAD2 regulated amyloid beta generation by activation of γ-secretase (49).
Our results showed that silencing OCIAD2 enhanced clonogenic survival of Sk-hep1 cells. Migration and invasion of cancer cells are essential processes during cancer metastatic procession, which account for more than 90% of cancer-associated mortality. Reduction of endogenous OCIAD2 by RNA interference dramatically promoted cell migration and invasion in Sk-hep1 HCC cells (Figure 4 ). Matrix metalloproteinases (MMPs), secreted by tumor cells, are extracellular matrix-degrading enzymes. The expression level of MMP9 was up-regulated in OCIAD2-shRNA cells (Figure 6 ). MMP9 (a 92-kDa gelatinase type IV collagenase [gelatinase B]) one of important MMPs, plays an important role in tumor invasion and angiogenesis (50) . It has been reported that MMP9 is predictive of a more invasive and metastatic character of HCC (51) . With respect to prognosis, increased MMP9 were found to exert an unfavorable impact on overall survival of patients with gastric carcinoma, HCC, and pancreatic adenocarcinoma (52) (53) (54) . MMP9 in HCC tumor tissues was highly expressed than the adjacent normal tissue (Figure 6 ), which was different from expression of OCIAD2. Overall survival analysis of TCGA data with enrolled HCC patients indicated that patients with higher ratio of OCIAD2/MMP9 were associated with a longer survival time.
Molecular signal pathway analysis indicated phosphorylation of Akt and focal adhesion kinase (FAK) were both increased by silencing OCIAD2 in the Sk-hep1 cells (See Figure 5A) . FAK, a non-receptor protein tyrosine kinase, has been suggested to play a critical role in HCC invasion and metastasis through MMP9 (55) . Phosphorylated Akt signaling pathway is one of downstream effectors of FAK and involved in invasion and metastasis of cancer (56) . Accumulated data have shown that activation of the Akt signaling pathway enhances metastasis via upregulating MMP9 in several cancers (55, 57) . It also has been reported colonies formation of liver cancer cells was positively correlated with the level of Akt activation (58) . Our result shows that inhibition of Akt restored OCIAD2 knocking-down-mediated increase in HCC cell invasion and clonogenic survival, suggesting a regulatory role of AKT in this process.
Biomarkers for HCC are important for diagnosis, monitoring of tumor aggressiveness, treatment responsiveness, recurrence and survival. Alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) are two widely used makers of HCC in clinic. While there is still room to development the sensitivity, diagnosis accuracy and specificity of the markers. Combination of biomarkers may be more valuable for the diagnosis, staging, and prognosis of HCC. We have compared the correlation of OCIAD2 with AFP and PIVKA-II. The correlation coefficient of OCIAD2 and AFP is −0.24 (Spearman's correlation, P = 0), and the correlation coefficient of OCIAD2 and ACE is −0.27 (Spearman's correlation, P = 0), indicating OCIAD2 displayed negative correlation with AFP and PIVKA-II. Comparing cancer vs normal gene expression profiles of TCGA HCC data, the value of OCIAD2 expression was −0.929, while AFP and PIVKA-II was 1.771 and 0.836.
Taken together, HCC patients data and in vitro studies indicate that epigenetic silence by hypermethylation leads to a reduced expression of OCIAD2. Downregulation of OCIAD2 by hypermethylation plays an important role in HCC tumor growth and invasion, which was reported in HCC cells for the first time. Hypermethylated OCIAD2 may contribute to HCC treatment development.
Materials and methods
HCC patient data on TCGA
We downloaded and analyzed data of HCC patients from TCGA (TCGA public data until Jun 11, 2015 http://tcga-data.nci.nih.gov/). In total, 371 HCC and 50 adjacent normal liver tissues with gene expression, DNA methylation and clinical follow-up data were analyzed. The gene expression data were normalized using the RNA normalization method described in the TCGA NCI Wiki.
Cell culture and treatment with 5-azacytidine
Sk-Hep1, Hep-G2, Hep-3B, C3A, SNU-182 and SNU-398 cell lines were obtained from ATCC (American Type Culture Collection, Rockville, MD) and maintained at 37°C in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum in a 5% CO2 atmosphere. 5-azacytidine (5-Aza) was purchased from Sigma (St. Louis, MO) and dissolved in DMSO. All the HCC cell lines were treated with 1, 5 or 10 µM 5-Aza (Sigma, St. Louis, MO) for 5 days. The culture medium was changed daily. The control cells were treated with an equal amount of vehicles.
Generation of stable OCIAD2 knocking-down cell line
OCIAD2 shRNA lentiviral particles were obtained from OriGene (Rockville, MD). Sk-hep1 cells were infected with OCIAD2 shRNA lentiviral particles following the manufacturer's instruction. The infection of Sk-hep1 cells with lentiviral particles to was according to the manufacturer's instruction. Briefly, one million of Sk-hep1 cells were seeded in a six-well plate on the day before infection. On day 2, the culture medium was replaced with the opti-MEM medium (Invitrogen, Carlsbad, CA) containing 8 μg/ ml polybrene (Sigma, St. Louis, MO) and shRNA lentiviral particles added into the culture. The infected cells were incubated overnight in the CO2 incubator. The medium was refreshed with FBS-containing DMEM at 48 h post-infection. Puromycine (2 μg/ml) was used for selection of the cells with stably transfected Sk-hep1. The knocking-down efficiency of OCIAD2 in the Sk-hep1 cells were determined using Real time-PCR and western blotting.
Western Blot
The cells were lysed with RIPA lysis buffer (Cell signaling Technology, Danvers, MA) supplemented with protease and phosphatase inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and stored in aliquots at −20°C until use. The protein concentration was determined using the BCA Kit (Thermo Fisher Scientific, San Jose, CA). Thirty micrograms of protein lysates were mixed with an equal volume of Laemmli sample buffer (250 mmol/l Tris, pH 7.4, 2% w/v SDS, 25% v/v glycerol, 10% v/v 2-mercaptoethanol, and 0.01% w/v bromophenol blue), denatured by boiling, and separated by SDS-PAGE (59). The separated proteins were then transferred to a nitrocellulose membrane (GE Healthcare, Pittsburgh, PA) in transfer buffer containing 25 mM Tris, pH 8.8, 192 mM glycine, and 10% v/v methanol at 100 volts for 60 min. All washing, blocking and antibody solutions were prepared in TBST. Membranes were blocked in 5% BSA (bovine serum albumin), followed by overnight incubation with primary antibodies. Antibodies used in the study included anti-OCIAD2, anti-phosphorylated FAK, anti-phosphorylated AKT, anti-phosphorylated ERK, anti-AKT and anti-β-actin (Cell signaling Technology, Danvers, MA). Membranes were then washed three times, followed by incubation with the secondary antibodies for 1hr. Immunoblots were developed using the enhanced chemiluminescence (ECL) reagent (Cell signaling Technology, Danvers, MA) and visualized using FluroChemQ processor (Proteinsimple, Santa Clara, CA). Densitometric analysis was performed following acquisition using ImageJ software (NIH).
RNA isolation and quantitative real-time PCR
RNA was isolated from cells by the RNeasy Mini Kit (Qiagen, Valencia, CA). One microgram of total RNA was reverse-transcribed according to the manufacturer's instructions using the SuperScript® III FirstStrand Synthesis Kit (Invitrogen, Carlsbad, CA). Quantitative Real-Time PCR was performed using the Power SYBR ® Green PCR Master Mix Kit (Applied Biosystems, Foster City, CA). β-actin was used for normalization. The relative expression levels were calculated using 2 −ΔΔCt . Primer sequences for OCIAD2, MMP9 and β-actin were as follows: OCIAD2,5'-TTTGGATCATTGCC CAAAGT,3'-TATGCTGTGGACCAAAACCA;MMP9,5'-GGCTTAGATCATTCCTCAGTG,3'-GCCATTCACGTC-GTCCTTAT; and β-actin, 5'-GGACTTCGAGCAAGAGATGG,3'-AGCACTGTGTTGGCGTACAG.
Clonogenic formation assay
Colony formation was performed as described previously (60) . Briefly, one thousand cells were plated into six-well plates. The cells were cultured for 10-14 days and fresh medium added in the culture plate every 3-4 days. Then cells were fixed in 25% methanol and stained with Crystal Violet (Fisher Scientific, Asheville, NC). The colonies were counted from two of three independent experiments per each treatment group.
Wound healing assay
The scratch motility assay was used to measure two-dimensional cancer cell movement as described earlier (61) . The cells were grown to full confluence in a six-well plate. A scratch was made on the cell monolayer using a sterile 200 μl pipette tip. The floating cells were removed by washing and then the culture plate was incubated in a complete medium for 6 h and 24 h. The wound healing was visualized and recorded under a light microscope (Olympus IX-71).
Cell invasion assay
For the cell invasion assay, the transwell inserts with 8 μm pores in a 24-wells format (Coring Costar, Cambridge, MA) were used according to the method described previously (61) . The transwell inserts were precoated with 200 µL 0.15% matrigel and incubated at 37°C overnight; 1 × 10 5 cells in serum-free culture medium were seeded into the insert. Each insert was placed in the lower chamber containing 10% FBS culture medium. Following 24 h incubation, the medium in the insert was removed and non-migrated cells were gently swabbed by Q-tips from the upper surface of the insert. The membrane was fixed with 20% methanol for 30 min at room temperature and then stained with crystal violet for 30 min. The cells attached to the bottom of polycarbonate membranes were counted. Each experiment was repeated three times.
Statistical analysis
Results were analyzed using two-tailed Student's t-test to assess statistical significance. The differences were considered as statistically significant when P < 0.05.
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Supplementary data are available at Carcinogenesis online.
